ChemoMetec (CHEMM) Q3 2026 earnings summary

Executive summary

• Revenue grew by 15% year-over-year in Q3 2025/26 to DKK 142.3 million; adjusted for a one-off IFRS-related effect, revenue increased by 2% to DKK 127.2 million.

• EBITDA rose 33% year-over-year to DKK 84.5 million; excluding the one-off, EBITDA was DKK 69.4 million, up 9% year-over-year.

• Strong growth in instrument sales, especially XcytoMatic products, offset by declines in consumables and non-priority business areas.

• Several new strategic partnerships established to drive automation in bioprocessing.

Financial highlights

• Q3 revenue: DKK 142.3 million (+15% year-over-year); adjusted: DKK 127.2 million (+2%).

• Q3 EBITDA: DKK 84.5 million (+33%); adjusted: DKK 69.4 million (+9%).

• EBITDA margin: 59% (Q3); adjusted: 55% (Q3), up from 51% last year.

• 9M revenue: DKK 391.3 million (+4%); 9M EBITDA: DKK 220.7 million (+11%).

Outlook and guidance

• Revenue guidance for 2025/26 maintained at DKK 505–525 million.

• EBITDA guidance for 2025/26 maintained at DKK 275–290 million.